Bruker (BRKR) Stock Price, News & Analysis

Company Overview

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies. Bruker also provides software, consumables, technical support and other services that help customers analyze samples and interpret scientific data.

Founded in the 1960s by Günther Laukien, Bruker has grown into an international provider serving academic, government, pharmaceutical, biotechnology, industrial and healthcare customers. The company is headquartered in Billerica, Massachusetts, and operates through a global network of facilities, sales organizations and service teams. Bruker has been led for many years by President and Chief Executive Officer Frank H. Laukien.

Key Stats

• Today's Range: $57.28 to $58.30
• 50-Day Range: $52.66 to $64.75
• 52-Week Range: $32.37 to $66.98
• Volume: 2.33 million shs
• Average Volume: 2.19 million shs
• Market Capitalization: $8.87 billion
• P/E Ratio: N/A
• Dividend Yield: 0.34%
• Price Target: $59.43
• Consensus Rating: Moderate Buy

Bruker Stock Analysis - MarketRank™

Bruker scored higher than 31% of companies evaluated by MarketBeat, and ranked 570th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bruker has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 2 strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Bruker is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Bruker has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.21%

Earnings Growth

Earnings for Bruker are expected to grow by 13.21% in the coming year, from $2.12 to $2.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bruker is -83.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bruker is -83.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Bruker has a PEG Ratio of 1.76. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bruker has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.43% of the float of Bruker has been sold short.

Short Interest Ratio / Days to Cover

Bruker has a short interest ratio ("days to cover") of 5.71.

Change versus previous month

Short interest in Bruker has recently increased by 2.15%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Bruker has a dividend yield of 0.35%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bruker does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Bruker will have a dividend payout ratio of 8.33% next year. This indicates that Bruker will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Bruker this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for BRKR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Bruker to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bruker insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,740.00 in company stock.

Percentage Held by Insiders

27.20% of the stock of Bruker is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.52% of the stock of Bruker is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Record date for 10/7 Dividend: 9/21/2026
• Ex-Dividend for 10/7 Dividend: 9/21/2026
• Dividend Payable: 10/07/2026
• Today: 10/27/2026
• Next Earnings (Confirmed): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:BRKR
• CIK: 1109354
• Web: www.bruker.com
• Phone: (978) 663-3660
• Fax: 978-663-5585
• Employees: 11,085
• Year Founded: 1960

Price Target and Rating

• Average Price Target for Bruker: $59.43
• High Price Target: $80.00
• Low Price Target: $35.00
• Potential Upside/Downside: +2.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 27.47
• P/E Growth: 1.76
• Net Income: -$8.60 million
• Net Margins: -2.35%
• Pretax Margin: -0.64%
• Return on Equity: 12.47%
• Return on Assets: 4.91%

Debt

• Debt-to-Equity Ratio: 0.76
• Current Ratio: 1.85
• Quick Ratio: 0.92

Sales & Book Value

• Annual Sales: $3.44 billion
• Price / Sales: 2.58
• Cash Flow: $3.41 per share
• Price / Cash Flow: 17.06
• Book Value: $16.28 per share
• Price / Book: 3.58

Miscellaneous

• Outstanding Shares: 152,360,000
• Free Float: 110,917,000
• Market Cap: $8.87 billion
• Optionable: Optionable
• Beta: 1.22